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in the pathogenesis of osteoarthritis (OA). In our previous study,
we demonstrated that oxidative stress induced the features of
chondrocyte senescence during the progression of OA.
Fullerene (C60) is spherical carbon molecules with a unique
cage structure. C60 is characterized as a strong radical sponge.
Recent report revealed that this compound has a high reactivity
with oxygen free radicals and their potential activity as free
radical scavengers. It has been demonstrated that C60 inhibits
neuronal apoptosis by scavenging oxygen reactive species. Also,
it has been demonstrated that C60 protects against human skin
keratinocytes from cell death after UV stress.
As above mentioned, there is evidence for oxidative damage by
reactive oxygen speaceis in OA cartilage. It is well known that ox-
idative stress (oxygen homeostasis and its down-regulation) are
closely involved in the pathogenesis of OA. Exploitation of C60
molecule could lead to the definition of new therapeutic strate-
gies in the prevention of both chondrocyte aging and cartilage
degeneration.
To prevent the degeneration of articular cartilage in OA, we
focused on C60, which acts a strong free radical scavenger, as
an anti-oxidative agent. We studied whether or not water-soluble
fullerene has a potential as a protective agent against catabolic
stress-induced degeneration of articular cartilage both in vitro
and in vivo.
Methods: i) In the presence or absence of water soluble C60
(50, 100 μM), human chondrocytes were incubated with IL-1 β
(10 ng/ml) or H2O2 (100 μM). After the incubation period, chon-
drocyte activity ((MMP-1, -3, -13 production, type II collagen and
aggrecan production, cellular apoptosis, cellular senescence)
was analyzed.
ii) OA rabbit model was produced by resection of both the anterior
cruciate ligament and the medial collateral ligament. 32 rabbits
(New Zealand White rabbits) were divided into 4 subgroups; 0.1
μM C60-treated group, 1.0 μM C60-treated group, 10.0 μM C60-
treated group, and 40.0 μM C60-treated group. In each rabbit
after surgical treatment, the left knee joint was treated by an
intra-articular injection of appropriate water-soluble C60 (2.0 ml)
once a week over 4 or 8 weeks. The right knee joint was also
treated by an intra-articular injection of 50% polyethyleneglycol
(2.0 ml) as a control once a week over 4 or 8 weeks. The rabbits
were euthanized 4 and 8 weeks after surgery and both knee
joints were harvested. Bone and cartilage tissue blocked were
prepared for histological analysis.
Results: C60 (50, 100 μM) inhibited the catabolic stress-induced
production of matrix degrading enzymes (MMP-1,-3, -13), apop-
tosis and premature senescence of chondrocytes in vitro. In
OA rabbit model, treatment with water-soluble C60 significantly
reduced the degeneration of articular cartilage, whereas the con-
trol knee joints showed the progression of cartilage degeneration
with time. We also observed the inhibitory effect of C60 on the
cartilage degeneration in a dose dependent manner in OA rabbit
model.
Conclusions: We confirmed that C60 inhibited the catabolic
stress-induced production of matrix degrading enzymes, down-
regulated production of matrix proteins, cellular senescence and
apoptosis in cultured chondrocytes in vitro. Also, our in vivo
study with OA rat model indicate that C60 fullerene may be a
therapeutic agent to protect the articular cartilage with advance
of cartilage degeneration in OA.
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THE EFFECTS OF FOOTWEAR ON DYNAMIC LOADING
OF THE KNEE IN HEALTHY SUBJECTS
N. Shakoor, R.H. Lidtke, J.A. Block
Rush Medical College, Chicago, IL
Purpose: Dynamic joint loading is an important factor in the
pathophysiology of osteoarthritis (OA) of the knee, and the preva-
lence and progression of knee OA are known to be associated
with high dynamic loading (i.e. peak external knee adduction
moment). We have previously demonstrated that in subjects
with knee OA, walking barefoot significantly decreases the peak
external knee adduction moment compared to walking with stan-
dard walking shoes (Arthritis Rheum, in press). Subsequently,
we designed a shoe to incorporate the essential "unloading"
characteristics of barefoot walking. Here, we test the hypothesis
that barefoot walking reduces knee loading in normal healthy
individuals as well as in OA, and thus that normal subjects will
exhibit significantly reduced knee loading when walking barefoot
and when walking with our "unloading" shoes compared to their
"usual" walking shoes.
Methods: Twenty-six normal subjects underwent gait analyses
of their dominant limb using an optoelectronic camera system
and a multi-component force plate. Subjects were evaluated for
gait while wearing their self-selected "usual" walking shoes. In
addition, all of the subjects underwent gait analyses while bare-
foot and 19 underwent analyses with the "unloading" shoes. In
each case, subjects were permitted to acclimate to the new con-
dition prior to gait testing. Subjects walked at their normal walk-
ing speed, and comparisons were performed on runs matched
for speed. The peak external knee adduction moment (%body
weight * height) was calculated at the knee and used as the pri-
mary endpoint. Paired t-tests were used to compare differences
in the moment during the different "footwear" conditions.
Results: 18 females and 8 males were evaluated, with mean age
(±SD) of 42±13 years. There were no significant differences in
speed during the three walking conditions. Overall, a significant
reduction in the peak external knee adduction moment was noted
during barefoot walking (2.0 ±0.7 vs 2.3±0.8, p=0.023) and while
walking with the "unloading" shoe (2.0±0.9 vs 2.3±0.8, p=0.009)
compared to "usual" walking shoes. These results corresponded
to a 13% reduction the peak external knee adduction moment
during the barefoot and "unloading" shoe conditions.
Conclusions: This study demonstrates that the reduction in
medial knee loading during barefoot walking that was previously
observed in knee OA patients is a general phenomenon that also
applies to normal individuals. Furthermore, a shoe designed to
incorporate the biomechanical advantages of barefoot walking
effectively reduces the dynamic knee loads in normal individuals
during gait relative to loading with usual footwear. In light of
these findings in normal individuals, closer examination of the
design and biomechanical effects of modern footwear on lower
extremity joint loading is warranted, both in healthy individuals
who may be at risk for OA as well as in those with established
OA.
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Purpose: The Glucosamine/chondroitin Arthritis Intervention
Trial (GAIT) was a double-blind, placebo-controlled, random-
ized, clinical trial comparing glucosamine (G), chondroitin sulfate
(CS), the combination of G and CS, and celecoxib (CE) to
placebo (PL). No treatment differences were observed among
the dietary supplements in the primary analysis. We report treat-
ment effects in a subgroup analysis of patients with potentially
milder disease.
Methods: GAIT patients were required to have clinical and ra-
diographic OA and a summed WOMAC Pain score of 125-400
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mm. GAIT patients who did not experience OA flare, defined
as increases of (a) 15 mm in WOMAC walking pain and (b)
Likert Physician Global of Disease Severity ≥1, between screen-
ing and randomization visits had a lower placebo response rate
and may have improved ability to discriminate among treatment
groups. Response was defined as 20% improvement in summed
WOMAC Pain between randomization and 6 months of treatment,
and by OMERACT-OARSI criteria. This abstract reports differ-
ences noted in chondroitin sulfate response in these "non-flare"
patients.
Results: Results: 1583 patients were recruited to GAIT. 1221
patients (77.1%) did not have flare as defined above. While
these patients were demographically similar to the overall group,
it was noted that chondroitin sulfate response seemed more pro-
nounced in the non-flare patients that may have less advanced
disease (WOMAC Pain 125-300mm; KL Grade 2) as detailed
below:
20% WOMAC Pain Response
G CS G+CS CE PL
WOMAC Pain =300mm 64.9% 66.7% 60.5% 68.8% 59.4%
WOMAC Pain 301-400mm 63.3% 54.5% 79.2% 69.0% 49.0%
KL Grade 2 65.4% 72.9% 68.5% 74.0% 60.6%
KL Grade 3 63.4% 53.6% 60.5% 61.4% 52.8%
OMERACT-OARSI Response
G CS G+CS CE PL
WOMAC Pain =300mm 59.5% 64.3% 61.0% 65.9% 56.1%
WOMAC Pain 301-400mm 63.3% 52.3% 73.6% 69.0% 43.1%
KL Grade 2 60.2% 70.8% 69.4% 69.9% 56.8%
KL Grade 3 60.4% 50.9% 58.1% 61.4% 49.1%
Conclusions: There may be a differential pain response in GAIT
patients with features that suggest relatively milder OA. The
effect of chondroitin sulfate on OA symptoms may be more pro-
nounced in these patients. Further understanding of the biologic
mechanisms of these agents is necessary.
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DOES THE CORRECTION OF FLEXED POSITION AND
LATERAL DEVIATION USING A SPLINT PROVIDE
THERAPEUTIC ADVANTAGE FOR PATIENTS WITH
OSTEOARTHRITIS OF THE DISTAL INTERPHALANGEAL
JOINTS?
Y. Toda, N. Tsukimura
Toda Orthopedic Rheumatology Clinic, Osaka, Japan
Purpose: Although symptomatic and radiographic osteoarthritis
(OA) of the distal interphalangeal (DIP) joints are common,
there have been few reports concerning the correction of flexed
position and lateral (ulnar or radial) deviation using a splint. We
modified 5-sting banjo finger picks made from tin to correct the
alignment of distal phalanges (the realignment splint) for the
patients with early-phase DIP OA.
Methods: The setting was an Outpatient clinic. Fifty-two patients
with a complaint of DIP joint pain at the single finger and Kellgren
and Lawrence radiographic grade of 2 or 3 at the painful DIP joint
were prospectively randomized and divided into three groups, a
group treated with the realignment splint (n=18), a group with a
placebo splint (n=17), or a group without a splint (n=17). The trial
lasted 4 weeks. The remission scores for the daily activity in the
Australian/Canadian (AUSCAN) Index and the visual analogue
scale (VAS) for subjective DIP joint pain were compared among
the three groups at the conclusion.
Results: The AUSCAN Index at the final assessment showed
significantly greater improvement in the realignment splint group
than in the no splint (p=0.024) and placebo splint (p=0.01)
groups. Similarly, there were significant differences in the change
of VAS between the no splint and realignment splint groups
(p=0.043), and between the realignment and placebo splint
groups (p=0.013).
Fig. 1. The realignment splint.
Conclusions: Through such studies, it will be meaningful to
develop an efficacious splint for patients with hand OA to im-
prove the quality of life while simultaneously reducing costs and
complications.
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Purpose: To assess the influence of patient preference on out-
come in an RCT of intra-articular corticosteroid (IS) and tidal
irrigation (TI) in patients with knee osteoarthritis (OA) and to
identify predictors of patient preference.
Methods: A 6 month, randomised, single blind, parallel group,
clinical trial of patients recruited from Rheumatology clinics with
symptomatic knee OA. Patients were randomised to IS with
40mg triamcinolone acetonide and 2mls of 1% lignocaine or TI
irrigating the knee with 500-1000 mls of normal saline through
a 3 mm diameter trochar. The primary outcome measure for
this analysis was change in WOMAC pain score (VAS). Before
randomization, patients were asked if they had a treatment
preference and this was categorised into: no preference (NP),
received their preference (RP) or did not receive their preference
(NRP). The response to intervention was compared across the
three groups and baseline characteristics were also explored.
Results: 150 subjects were randomised (65% women) and there
were 22 drop-outs (11 in each treatment arm). 79 patients
received IS and 71 TI. The numbers in each preference group
were: RP 44, NRP 60, NP 46. Patients with NP and RP had
significantly greater improvements at 24 weeks compared to
the NRP groups (Figure 1). The NRP patients did not achieve
any benefit at 24 weeks compared to baseline. The greatest
improvements were in those with NP and who received TI, the
worst outcome in those who preferred TI but received IS.
There was no difference between the three groups in clinical
characteristics including age, BMI, duration of disease, presence
of bilateral disease, radiographic severity, presence of effusions
or baseline WOMAC score. Baseline anxiety and depression
scores (HAD) were not different between the 3 groups, neither
was their rating of helplessness using a validated questionnaire.
Women were more likely to express a treatment preference
